Skip to main content

Periprosthetic Joint Infection (PJI)

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

TenNor Therapeutics
TenNor TherapeuticsChina - Suzhou
1 program
1
TNP-2092 for injectionPhase 1/21 trial
Active Trials
NCT06889701Recruiting33Est. Aug 2026

Trial Timeline

Clinical trial activity over time

2025
2026
TenNor TherapeuticsTNP-2092 for injection

Clinical Trials (1)

Total enrollment: 33 patients across 1 trials

NCT06889701TenNor TherapeuticsTNP-2092 for injection

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

Start: Apr 2025Est. completion: Aug 202633 patients
Phase 1/2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 33 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.